Dow Jones
39.512,84 +837,14 (+2,16%) Nasdaq
16.340,87 +184,57 (+1,14%) Nikkei 225
38.142,21 -86,90 (-0,23%) EUR/USD
1,0776 +0,0003 (+0,03%) Bitcoin EUR
56.679,74 +37,44 (+0,07%) CMC Crypto 200
1.254,62 -5,58 (-0,44%)
Zealand Pharma A/S (22Z.BE)
- GlobeNewswire
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease Press release – No. 12 / 2023 SYNCHRONIZE-1 and SYNCHRONIZE-2 are global Phase III studies of survodutide (BI 456906) in people living with obesity and overweight without and with type 2 diabetes, respectivelyA third study, SYNCHRONIZE-CVOT, is a global, long-term cardiovascular safety study of survodutide in people living with o
- GlobeNewswire
Total number of shares and voting rights in Zealand Pharma at September 29, 2023
Company announcement – No. 36 / 2023 Total number of shares and voting rights in Zealand Pharma at September 29, 2023 Copenhagen, Denmark, September 29, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a
- GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 35 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, September 14, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related secu
